The effect of Dulaglutide on glycemic and weight control in patients with type 2 diabetes

Abstract

Background and aims. The objectives of type 2 diabetes treatment are to achieve adequate long-term glycemic control and to reduce the risk associated with comorbidities and complications. Once-weekly Dulaglutide showed a reduction in cardiovascular risk associated with diabetes in addition to improved glycemic control and bodyweight reduction in several clinical trials. We aimed to investigate the effect of Dulaglutide 1.5 mg on glycemic and weight control in type 2 diabetes patients inadequately controlled by antihyperglycemic treatment in real-world clinical practice.
 Methods. We retrospectively reviewed the medical records of 50 patients with type 2 diabetes inadequately controlled by previous treatment and newly initiated on Dulaglutide. The data were collected at 6 months (n=50) and 12 months (n=40) after Dulaglutide therapy initiation.
 Results. Dulaglutide treatment resulted in significant improvement of glycated hemoglobin (−1.3 %; p<0.001) after 6 months and after 12 months (−2.0 %; p<0.001). Significant bodyweight reduction was found after 6 months (−2.0 kg; p=0.002) and 12 months (−3.5 kg; p=0.001) of Dulaglutide treatment initiation. In addition, a reduction in insulin dose was observed.
 Conclusions. Our clinical data showed that Dulaglutide 1.5 mg significantly improved glycemic and bodyweight control at 6 and 12 months after treatment initiation in patients with type 2 diabetes inadequately controlled by previous antihyperglycemic treatment.

Improving glycemic control: transitioning from dulaglutide to tirzepatide in patients with type 2 diabetes undergoing hemodialysis

“…Dulaglutide, a weekly formulation of the GLP-1 receptor agonists (GLP-1 RA) launched in Japan in 2015, is effective in reducing body weight, controlling fasting and postprandial glycemia, and has a positive effect on atherosclerotic cardiovascular outcomes ( Ruda et al, 2023 ). The current guidelines for managing type 2 diabetes recommend GLP-1 RAs as first-line injectable therapy even before insulin initiation ( American Diabetes Association Professional Practice Committee, 2022 ).…”